letrozol stada 2.5 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - letrozole - tabletti, kalvopäällysteinen - 2.5 mg - letrotsoli
letrozol ratiopharm 2.5 mg tabletti, kalvopäällysteinen
ratiopharm gmbh - letrozole - tabletti, kalvopäällysteinen - 2.5 mg - letrotsoli
xemestan 25 mg tabletti, kalvopäällysteinen
avansor pharma oy - exemestane - tabletti, kalvopäällysteinen - 25 mg - eksemestaani
letrozol orion 2.5 mg tabletti, kalvopäällysteinen
orion corporation - letrozolum - tabletti, kalvopäällysteinen - 2.5 mg - letrotsoli
verzenios
eli lilly nederland b.v. - abemaciclib - rintojen kasvaimet - antineoplastiset aineet - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.
everolimus avansor 2.5 mg tabletti
avansor pharma oy - everolimuusi - tabletti - 2.5 mg - everolimuusi
everolimus avansor 5 mg tabletti
avansor pharma oy - everolimuusi - tabletti - 5 mg - everolimuusi
everolimus avansor 10 mg tabletti
avansor pharma oy - everolimuusi - tabletti - 10 mg - everolimuusi
everolimus mylan 2.5 mg tabletti
mylan ab - everolimuusi - tabletti - 2.5 mg - everolimuusi
everolimus mylan 5 mg tabletti
mylan ab - everolimuusi - tabletti - 5 mg - everolimuusi